291 related articles for article (PubMed ID: 38379863)
1. Continuous glucose monitoring and advanced glycation endproducts for prediction of clinical outcomes and development of cystic fibrosis-related diabetes in adults with CF.
Scully KJ; Brenner L; Martin K; Ruazol M; Sawicki GS; Uluer A; Neuringer I; Yonker LM; Sicilian L; Putman MS
Front Endocrinol (Lausanne); 2024; 15():1293709. PubMed ID: 38379863
[TBL] [Abstract][Full Text] [Related]
2. Continuous Glucose Monitoring and HbA1c in Cystic Fibrosis: Clinical Correlations and Implications for CFRD Diagnosis.
Scully KJ; Sherwood JS; Martin K; Ruazol M; Marchetti P; Larkin M; Zheng H; Sawicki GS; Uluer A; Neuringer I; Yonker LM; Sicilian L; Wexler DJ; Putman MS
J Clin Endocrinol Metab; 2022 Mar; 107(4):e1444-e1454. PubMed ID: 34850006
[TBL] [Abstract][Full Text] [Related]
3. The effect of elexacaftor/tezacaftor/ivacaftor (ETI) on glycemia in adults with cystic fibrosis.
Scully KJ; Marchetti P; Sawicki GS; Uluer A; Cernadas M; Cagnina RE; Kennedy JC; Putman MS
J Cyst Fibros; 2022 Mar; 21(2):258-263. PubMed ID: 34531155
[TBL] [Abstract][Full Text] [Related]
4. Can continuous glucose monitoring predict cystic fibrosis-related diabetes and worse clinical outcome?
Zorron M; Marson FAL; Morcillo AM; Gonçalves AC; El Beck MS; Ribeiro JD; Ribeiro AF
J Bras Pneumol; 2022; 48(2):e20210307. PubMed ID: 35475864
[TBL] [Abstract][Full Text] [Related]
5. Hemoglobin A
Chan CL; Hope E; Thurston J; Vigers T; Pyle L; Zeitler PS; Nadeau KJ
Diabetes Care; 2018 Jul; 41(7):1406-1413. PubMed ID: 29674323
[TBL] [Abstract][Full Text] [Related]
6. Decline in HbA1c during the first year of elexacaftor/tezacaftor/ivacaftor treatment in the Danish cystic fibrosis cohort: Short title: Decline in HbA1c after elexacaftor/tezacaftor/ivacaftor treatment.
Nielsen BU; Olsen MF; Mabuza Mathiesen IH; Pressler T; Ritz C; Katzenstein TL; Olesen HV; Skov M; Jensen-Fangel S; Almdal TP; Faurholt-Jepsen D
J Cyst Fibros; 2024 Jan; 23(1):103-108. PubMed ID: 37989700
[TBL] [Abstract][Full Text] [Related]
7. The Relationship Between Continuous Glucose Monitoring and OGTT in Youth and Young Adults With Cystic Fibrosis.
Chan CL; Pyle L; Vigers T; Zeitler PS; Nadeau KJ
J Clin Endocrinol Metab; 2022 Jan; 107(2):e548-e560. PubMed ID: 34537845
[TBL] [Abstract][Full Text] [Related]
8. Oral glucose tolerance test and continuous glucose monitoring to assess diabetes development in cystic fibrosis patients.
Clemente León M; Bilbao Gassó L; Moreno-Galdó A; Campos Martorrell A; Gartner Tizzano S; Yeste Fernández D; Carrascosa Lezcano A
Endocrinol Diabetes Nutr (Engl Ed); 2018 Jan; 65(1):45-51. PubMed ID: 29137964
[TBL] [Abstract][Full Text] [Related]
9. Glucose >200 mg/dL during Continuous Glucose Monitoring Identifies Adult Patients at Risk for Development of Cystic Fibrosis Related Diabetes.
Taylor-Cousar JL; Janssen JS; Wilson A; Clair CG; Pickard KM; Jones MC; Brayshaw SJ; Chacon CS; Barboa CM; Sontag MK; Accurso FJ; Nichols DP; Saavedra MT; Nick JA
J Diabetes Res; 2016; 2016():1527932. PubMed ID: 27999822
[No Abstract] [Full Text] [Related]
10. [Value of continuous glucose monitoring in screening for diabetes in cystic fibrosis].
Khammar A; Stremler N; Dubus JC; Gross G; Sarles J; Reynaud R
Arch Pediatr; 2009 Dec; 16(12):1540-6. PubMed ID: 19854630
[TBL] [Abstract][Full Text] [Related]
11. Glycemia and β-cell function before and after elexacaftor/tezacaftor/ivacaftor in youth and adults with cystic fibrosis.
Chan CL; Granados A; Moheet A; Singh S; Vigers T; Arbeláez AM; Yi Y; Hu S; Norris AW; Ode KL
J Clin Transl Endocrinol; 2022 Dec; 30():100311. PubMed ID: 36620757
[TBL] [Abstract][Full Text] [Related]
12. Use of hemoglobin A1c to identify dysglycemia in cystic fibrosis.
Darukhanavala A; Van Dessel F; Ho J; Hansen M; Kremer T; Alfego D
PLoS One; 2021; 16(4):e0250036. PubMed ID: 33882078
[TBL] [Abstract][Full Text] [Related]
13. Glycemic indices at night measured by CGM are predictive for a lower pulmonary function in adults but not in children with cystic fibrosis.
Declercq D; Helleputte S; Marchand S; Van Aken S; Van Braeckel E; Van Daele S; T'Sjoen G; Van Biervliet S; Lapauw B
J Cyst Fibros; 2023 Jan; 22(1):59-65. PubMed ID: 36068119
[TBL] [Abstract][Full Text] [Related]
14. MARKEDLY DELAYED INSULIN SECRETION AND A HIGH RATE OF UNDETECTED OVERT DIABETES CHARACTERIZE GLUCOSE METABOLISM IN ADULT PATIENTS WITH CYSTIC FIBROSIS AFTER LUNG TRANSPLANTATION.
Winhofer Y; Wolf P; Fellinger P; Tura A; Hillebrand P; Staufer K; Trauner M; Jaksch P; Muraközy G; Kautzky-Willer A; Pacini G; Krebs M; Luger A; Kazemi-Shirazi L
Endocr Pract; 2019 Mar; 25(3):254-262. PubMed ID: 30913015
[TBL] [Abstract][Full Text] [Related]
15. Screening for cystic fibrosis-related diabetes and prediabetes: Evaluating 1,5-anhydroglucitol, fructosamine, glycated albumin, and hemoglobin A1c.
Tommerdahl KL; Brinton JT; Vigers T; Nadeau KJ; Zeitler PS; Chan CL
Pediatr Diabetes; 2019 Dec; 20(8):1080-1086. PubMed ID: 31469470
[TBL] [Abstract][Full Text] [Related]
16. The Effects of Elexacaftor, Tezacaftor, and Ivacaftor (ETI) on Blood Glucose in Patients With Cystic Fibrosis: A Systematic Review.
Salazar-Barragan M; Taub DR
Cureus; 2023 Jul; 15(7):e41697. PubMed ID: 37575762
[TBL] [Abstract][Full Text] [Related]
17. Continuous glucose monitoring indices predict poor FEV
Pallin M; Kumar S; Daley C; Dawadi S; Leong P; Carr E; Soldatos G
J Cyst Fibros; 2021 Sep; 20(5):785-791. PubMed ID: 33781701
[TBL] [Abstract][Full Text] [Related]
18. A glycosylated hemoglobin A1c above 6% (42 mmol/mol) is associated with a high risk of developing Cystic Fibrosis-Related Diabetes and a lower probability of weight gain in both adults and children with Cystic Fibrosis.
Potter KJ; Racine F; Bonhoure A; Boudreau V; Bélanger N; Coriati A; Shohoudi A; Lavoie A; Senior PA; Mailhot G; Rabasa-Lhoret R
Diabetes Metab; 2023 Jul; 49(4):101455. PubMed ID: 37271306
[TBL] [Abstract][Full Text] [Related]
19. Peak OGTT glucose is associated with lower lung function in young children with cystic fibrosis.
Prentice BJ; Chelliah A; Ooi CY; Hameed S; Verge CF; Plush L; Widger J
J Cyst Fibros; 2020 Mar; 19(2):305-309. PubMed ID: 31126898
[TBL] [Abstract][Full Text] [Related]
20. Early assessment of glucose abnormalities during continuous glucose monitoring associated with lung function impairment in cystic fibrosis patients.
Leclercq A; Gauthier B; Rosner V; Weiss L; Moreau F; Constantinescu AA; Kessler R; Kessler L
J Cyst Fibros; 2014 Jul; 13(4):478-84. PubMed ID: 24359972
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
